Edition:
India

Histogenics Corp (HSGX.OQ)

HSGX.OQ on NASDAQ Stock Exchange Capital Market

2.60USD
20 Aug 2018
Change (% chg)

$-0.04 (-1.52%)
Prev Close
$2.64
Open
$2.60
Day's High
$2.62
Day's Low
$2.54
Volume
21,789
Avg. Vol
16,517
52-wk High
$3.26
52-wk Low
$1.61

Latest Key Developments (Source: Significant Developments)

Histogenics Files For Mix Shelf Offering Of Up To $75 Mln
Saturday, 18 Aug 2018 

Aug 17 (Reuters) - Histogenics Corp ::HISTOGENICS CORP FILES FOR MIX SHELF OFFERING OF UP TO $75 MILLION - SEC FILING.  Full Article

Histogenics Corp Q2 Loss Per Share $0.13
Thursday, 9 Aug 2018 

Aug 9 (Reuters) - Histogenics Corp ::ANNOUNCES SECOND QUARTER 2018 FINANCIAL AND OPERATING RESULTS.Q2 LOSS PER SHARE $0.13.Q2 EARNINGS PER SHARE VIEW $-0.23 -- THOMSON REUTERS I/B/E/S.INITIATION OF PHASE 3 CLINICAL TRIAL IN JAPAN EXPECTED IN SECOND HALF OF 2018.AS OF JUNE 30, 2018, HISTOGENICS HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $8.8 MILLION.BELIEVES ITS CURRENT CASH POSITION WILL BE SUFFICIENT TO FUND ITS OPERATIONS INTO Q4 OF 2018.  Full Article

Histogenics Enters Equity Distribution Deal
Thursday, 15 Mar 2018 

March 15 (Reuters) - Histogenics Corp ::HISTOGENICS - ENTERED EQUITY DISTRIBUTION DEAL WHERE CO MAY SELL SHARES OF COMMON STOCK HAVING OFFERING PRICE UP TO $10 MILLION VIA AGENT - SEC FILING.  Full Article

Histogenics And Medinet Enter Licensing Agreement For Commercialization Of NeoCart In Japan
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - Medinet Co Ltd <2370.T>::HISTOGENICS CORPORATION AND MEDINET CO., LTD ENTER INTO LICENSING AGREEMENT FOR DEVELOPMENT AND COMMERCIALIZATION OF NEOCART FOR THE JAPANESE MARKET.HISTOGENICS - TRANSACTION TERMS INCLUDE A $10 MILLION UP-FRONT PAYMENT WITH A POTENTIAL OF $87 MILLION IN TOTAL MILESTONES, AND TIERED ROYALTIES ON SALES.HISTOGENICS - PLANS TO INITIATE PHASE 3 CLINICAL TRIAL IN JAPAN IN SECOND HALF OF 2018 WITH POTENTIAL COMMERCIALIZATION IN JAPAN IN 2021 FOR NEOCART.  Full Article

MEDINET signs license contract for NeoCart with Histogenics
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - MEDINET Co Ltd <2370.T> ::Says it entered into a license contract for development and sale of autologous cultured chondrocyte named NeoCart, with Histogenics Corp <<>>.  Full Article

Histogenics Corp announces Q3 loss per share $0.23
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Histogenics Corp :Histogenics Corporation announces third quarter 2017 financial and operating results.Q3 loss per share $0.23.Q3 earnings per share view $-0.28 -- Thomson Reuters I/B/E/S.Histogenics Corp - ‍Potential biologics license application filing remain on track for Q3 of 2018​.Histogenics Corp - ‍Believes its current cash position will be sufficient to fund its operations into middle of 2018​.Histogenics - ‍As of September 30, 2017, co had cash, cash equivalents and marketable securities of $12.6 million, compared to $31.9 million at December 31, 2016​.  Full Article